Inventor · disambiguated record
Lan Huang
Also filed as: HUANG LAN · HUANG LAN-HSIANG
38 granted patents·23 pending applications·290 citations·filing 1995–2025
97Inventor score
Files withBEYONDSPRING PHARMACEUTICALS INC34UNIV CALIFORNIA7HUANG LAN5MBT HOLDING AG3APEX BIOTECHNOLOGY CORP2
Top patents by PatentIndex Score
61 records- 0197US10550104B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Feb 4, 2020·14 cites·20 claims
- 0296US11045467B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Granted Jun 29, 2021·7 cites·20 claims
- 0396US10357491B2Method of treating a brain tumorBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Jul 23, 2019·13 cites·20 claims
- 0496US10238650B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·18 cites·24 claims
- 0596US10155748B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Dec 18, 2018·15 cites·9 claims
- 0695US11254657B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Granted Feb 22, 2022·5 cites·16 claims
- 0794US12024501B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Jul 2, 2024·4 cites·20 claims
- 0893US11918574B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Granted Mar 5, 2024·2 cites·20 claims
- 0993US10668063B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Granted Jun 2, 2020·12 cites·21 claims
- 1093US10076518B2Method of treating a brain tumorBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Sep 18, 2018·15 cites·19 claims
- 1192US11229642B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Jan 25, 2022·6 cites·25 claims
- 1292US10912748B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Feb 9, 2021·8 cites·18 claims
- 1391US11857522B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Granted Jan 2, 2024·2 cites·26 claims
- 1489US6267814B1Cementitious dry cast mixtureMBT HOLDING AG·Filed 1999·Granted Jul 31, 2001·73 cites·41 claims
- 1588US11786523B2Composition and method for reducing thrombocytopeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Granted Oct 17, 2023·3 cites·31 claims
- 1688US10596169B2Cancer treatment with combination of plinabulin and taxaneBEYONDSPRING INC·Filed 2013·Granted Mar 24, 2020·16 cites·6 claims
- 1786US11400086B2Method of reducing chemotherapy-induced neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Aug 2, 2022·5 cites·19 claims
- 1882US2024425485A1Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1981US11633393B2Tubulin binding compounds and therapeutic use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Apr 25, 2023·2 cites·2 claims
- 2080US12377094B2Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapiesBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·22 claims
- 2176US8617543B2Modified mutant collagenase and its use in fat melting and in scar reductionHUANG LAN·Filed 2008·Granted Dec 31, 2013·7 cites·16 claims
- 2275US12458638B2Method of stimulating neutrophil survival and reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·21 claims
- 2371US12458639B2Tubulin binding compounds and therapeutic use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2023·Granted Nov 4, 2025·0 cites·2 claims
- 2470US7254042B2Electro magnetic interference shielding device and a liquid crystal display device adopting sameHON HAI PREC IND CO LTD·Filed 2005·Granted Aug 7, 2007·4 cites·16 claims
- 2568US12466811B2Mass spectrometry cleavable heterobifunctional photoactivated cross-linkersUNIV CALIFORNIA·Filed 2022·Granted Nov 11, 2025·0 cites·12 claims
- 2668US9222943B2Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and method of using sameRYCHNOVSKY SCOTT·Filed 2012·Granted Dec 29, 2015·3 cites·10 claims
- 2768US2025375440A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2867US12433886B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Oct 7, 2025·0 cites·19 claims
- 2967US6461425B2Cementitious dry cast mixtureMBT HOLDING AG·Filed 2001·Granted Oct 8, 2002·9 cites·28 claims
- 3066US10393752B2Mass spectrometry-cleavable cross-linking agentsUNIV CALIFORNIA·Filed 2016·Granted Aug 27, 2019·1 cites·26 claims
- 3166US5634972AHydration control of cementitious systemsSANDOZ LTD·Filed 1996·Granted Jun 3, 1997·23 cites·33 claims
- 3265US2024197723A1Therapeutic compositions and methods for treating tumorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3364US2024353418A1Mass spectrometry-cleavable haloacetamide-based cross-linkers and uses thereofUNIV CALIFORNIA·Filed 2024·Application pending·0 cites
- 3463US2025152473A1Stable plinabulin formulations and methods of their preparation and useBEYONDSPRING PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3563US2025073230A1Use of plinabulin in combination with immune checkpoint inhibitorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3658US8637467B2Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereofHUANG LAN·Filed 2009·Granted Jan 28, 2014·0 cites·12 claims
- 3758US2024408082A1Methods for treating cancers and tumorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3857US11603352B2Mass spectromeiry-cleavable cross-linkerUNIV CALIFORNIA·Filed 2020·Granted Mar 14, 2023·0 cites·13 claims
- 3956US2025389728A1Novel class of trioxane-based ms-cleavable cross-linkers to advance protein-protein interaction studies using cross-linking mass spectrometryUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 4055US5895525ARapid setting cementitious compositions and methodMBT HOLDING AG·Filed 1997·Granted Apr 20, 1999·12 cites·13 claims
- 4155US2023181605A1Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicityBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4254US8507562B2Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereofHUANG LAN·Filed 2007·Granted Aug 13, 2013·0 cites·18 claims
- 4353US5591259ARapid setting cementitious compositions and methodSANDOZ LTD·Filed 1995·Granted Jan 7, 1997·11 cites·9 claims
- 4453US2024368126A1Impurity in plinabulin or preparation thereof, and use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4552US2020281921A1Cancer treatment with combination of plinabulin and taxaneBEYONDSPRING INC·Filed 2020·Application pending·0 cites
- 4652US2021161888A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4752US2024299377A1Methods and compositions for treating iron disordersBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4851US9039877B2Electrode strip and sensor strip and manufacture method thereof and system thereofAPEX BIOTECHNOLOGY CORP·Filed 2012·Granted May 26, 2015·0 cites·11 claims
- 4951US2021177952A1Method and composition for stimulating immune responseBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 5050US2023035763A1Methods of treating cancer using tubulin binding agentsBEYONDSPRING PHARNACEUTICALS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lan Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →